How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

333 results for

Medication Causes of Gynecomastia

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Medication Causes of Gynecomastia

Medication Causes of Gynecomastia Medication Causes of Gynecomastia Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Medication Causes (...) of Gynecomastia Medication Causes of Gynecomastia Aka: Medication Causes of Gynecomastia , Drug-Induced Gynecomastia , Gynecomastia Secondary to Medication From Related Chapters II. Causes: Recreational and Illicit Drug use Anti-androgen (also contains s) Miscellaneous s s (see below under hormonal agents) III. Causes: Chemotherapy Anti-androgens s (Cuprimine) Cisplatin Vinca alkaloids IV. Causes: Antimicrobial Anti-androgens ( ) Miscellaneous agents ( ) (Minocin) V. Causes: Gastrointestinal Anti-androgens

2018 FP Notebook

2. Bilateral Mastectomy as Radical Treatment of Gynecomastia Secondary to Antiretroviral Therapy in a Low-Income Setting: A Case Report (PubMed)

Bilateral Mastectomy as Radical Treatment of Gynecomastia Secondary to Antiretroviral Therapy in a Low-Income Setting: A Case Report Gynecomastia is a common finding in males, with an incidence that varies widely globally. In 10-25% of cases, it is caused by drugs. Its pathophysiologic mechanism includes exposure to exogenous estrogens and medications that cause hypogonadism, antiandrogenic effects and hyperprolactinemia. Gynecomastia is associated with exposure to antiretroviral therapy (ART

Full Text available with Trip Pro

2018 Drug Safety - Case Reports

3. An infertile man with gynecomastia caused by a novel mutation of the androgen receptor gene (PubMed)

An infertile man with gynecomastia caused by a novel mutation of the androgen receptor gene 25532578 2016 02 11 2018 11 13 1745-7262 17 3 2015 May-Jun Asian journal of andrology Asian J. Androl. An infertile man with gynecomastia caused by a novel mutation of the androgen receptor gene. 509-10 10.4103/1008-682X.143740 Xu Hui-Ying HY Li Cheng-Di CD Tang Li-Li LL Wang Ling-Ling LL Yu Xia X Gu Xue-Mei XM Lin Xiang-Yang XY Clinical Laboratory Diagnostic Centre, The First Affiliated Hospital (...) of Wenzhou Medical University, Wenzhou 325000, China. Chen Bi-Cheng BC Department of Surgery, Wenzhou Key Laboratory of Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China. eng Case Reports Letter Research Support, Non-U.S. Gov't China Asian J Androl 100942132 1008-682X 0 Receptors, Androgen 3XMK78S47O Testosterone IM Adult Amino Acid Sequence Exons genetics Gynecomastia blood diagnosis genetics Humans Infertility, Male blood diagnosis genetics Male Molecular

Full Text available with Trip Pro

2014 Asian journal of andrology

4. Gynecomastia

indications Palpable testicular mass Gynecomastia size >5 cm Persistent Gynecomastia without obvious cause Serum HCG increased Breast (and possibly FNA) indications suspected MRI brain suspected (increased ) IX. Management Evaluate for underlying cause Physiologic cause is a diagnosis of exclusion Observation Indicated in most cases Routine follow-up on an every 6 month basis Medical management Indicated in symptomatic or distressing Gynecomastia 10 mg daily for 3 months ( ) 60 mg daily for 3-9 months (...) Enlargement , Benign Gynecomastia of Adolescence , Familial Gynecomastia II. Causes: Physiologic in Newborn, Puberty, Older men Physiologic Mechanisms excess Decreased androgen to ratio Physiologic syndromes (25% of cases) Gynecomastia in the newborn Common response to maternal s enlargement usually resolves in weeks May be accompanied by milk discharge (witch's milk) Benign Gynecomastia of Adolescence Frequently occurs in boys at mid to late Asymmetric involvement and tenderness Resolves spontaneously

2018 FP Notebook

5. Medication Causes of Gynecomastia

Medication Causes of Gynecomastia Medication Causes of Gynecomastia Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Medication Causes (...) of Gynecomastia Medication Causes of Gynecomastia Aka: Medication Causes of Gynecomastia , Drug-Induced Gynecomastia , Gynecomastia Secondary to Medication From Related Chapters II. Causes: Recreational and Illicit Drug use Anti-androgen (also contains s) Miscellaneous s s (see below under hormonal agents) III. Causes: Chemotherapy Anti-androgens s (Cuprimine) Cisplatin Vinca alkaloids IV. Causes: Antimicrobial Anti-androgens ( ) Miscellaneous agents ( ) (Minocin) V. Causes: Gastrointestinal Anti-androgens

2015 FP Notebook

6. Mastectomy for gynecomastia

Mastectomy for gynecomastia Mastectomy for gynecomastia Mastectomy for gynecomastia Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mastectomy for gynecomastia. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2010 Authors' objectives Gynecomastia is a benign enlargement of the male breast that is caused by an imbalance in the ratio of circulating (...) male hormone (testosterone) to female hormone (estrogen). Gynecomastia occurs with normal hormonal changes during puberty or aging, but is also associated with other conditions or drugs that alter the hormonal ratio. Gynecomastia is characterized by the growth of glandular tissue within the breast, the growth of glandular tissue and fatty tissue deposits, or by an accumulation of fatty tissue alone. The condition is often associated with pain or tenderness that warrants medical intervention

2010 Health Technology Assessment (HTA) Database.

7. Gynecomastia (Treatment)

disorder often alleviates breast enlargement. [ ] If hypogonadism (primary or secondary) is the cause of gynecomastia, parenteral or transdermal testosterone replacement therapy is instituted. However, testosterone does have the potential to exacerbate gynecomastia through the aromatization of the exogenous hormone into estradiol. For patients with idiopathic gynecomastia or with residual gynecomastia after treatment of the primary cause, medical or surgical treatment may be considered. A major factor (...) that should influence the initial choice of therapy for gynecomastia is the condition’s duration. It is unlikely that any medical therapy will result in significant regression in the late fibrotic stage (a duration of 12mo or longer) of gynecomastia. As a result, medical therapies, if used, should be tried early in the condition's course. The diagram below is a suggested treatment approach for patients presenting with breast enlargement. Suggested algorithm for the management of gynecomastia. A study

2014 eMedicine.com

8. Gynecomastia (Overview)

for physiologic gynecomastia Pubertal gynecomastia resolves spontaneously within several weeks to 3 years in most patients; breasts larger than 4 cm in diameter may not regress completely Identifying and managing an underlying primary disorder often alleviates breast enlargement For patients with idiopathic gynecomastia or with residual gynecomastia after treatment of the primary cause, medical or surgical treatment may be considered. If medical therapies are used, they should be tried early (...) of testosterone production in the aging testes most often account for gynecomastia in adult males. Older men are also more likely to take medications associated with gynecomastia than are younger men. Rarely, hyperprolactinemia may lead to gynecomastia through its effects on the hypothalamus to cause central hypogonadism. [ , ] Prolactin has also been reported to decrease androgen receptors and increase estrogen and progesterone receptors in breast cancer cells, which can lead to male gynecomastia. Prolactin

2014 eMedicine.com

9. Gynecomastia (Follow-up)

disorder often alleviates breast enlargement. [ ] If hypogonadism (primary or secondary) is the cause of gynecomastia, parenteral or transdermal testosterone replacement therapy is instituted. However, testosterone does have the potential to exacerbate gynecomastia through the aromatization of the exogenous hormone into estradiol. For patients with idiopathic gynecomastia or with residual gynecomastia after treatment of the primary cause, medical or surgical treatment may be considered. A major factor (...) that should influence the initial choice of therapy for gynecomastia is the condition’s duration. It is unlikely that any medical therapy will result in significant regression in the late fibrotic stage (a duration of 12mo or longer) of gynecomastia. As a result, medical therapies, if used, should be tried early in the condition's course. The diagram below is a suggested treatment approach for patients presenting with breast enlargement. Suggested algorithm for the management of gynecomastia. A study

2014 eMedicine.com

10. Gynecomastia (Diagnosis)

for physiologic gynecomastia Pubertal gynecomastia resolves spontaneously within several weeks to 3 years in most patients; breasts larger than 4 cm in diameter may not regress completely Identifying and managing an underlying primary disorder often alleviates breast enlargement For patients with idiopathic gynecomastia or with residual gynecomastia after treatment of the primary cause, medical or surgical treatment may be considered. If medical therapies are used, they should be tried early (...) of testosterone production in the aging testes most often account for gynecomastia in adult males. Older men are also more likely to take medications associated with gynecomastia than are younger men. Rarely, hyperprolactinemia may lead to gynecomastia through its effects on the hypothalamus to cause central hypogonadism. [ , ] Prolactin has also been reported to decrease androgen receptors and increase estrogen and progesterone receptors in breast cancer cells, which can lead to male gynecomastia. Prolactin

2014 eMedicine.com

11. Gynecomastia

of Aegina in the seventh century AD, who referred to the condition as an "effeminacy of men." Several medical and surgical treatments of gynecomastia were described in the 1800s. Treatment of gynecomastia has continued to evolve over the ages. Presently, a multifaceted surgical approach is used to optimize correction of the deformity. The fatty component is removed with one or a combination of the variants of liposuction, while the glandular component requires direct excision. The skin is redraped over (...) causes of the condition and its psychological impact. After initial presentation, boys are frequently advised to ignore the gynecomastia and are told that it will go away. Fortunately, in most instances, cases of minimal subareolar pubertal-onset gynecomastia do regress as puberty progresses. Individuals with no regression or even progression of the deformity often receive little or no understanding about the shame and humiliation they experience. Coaches, sergeants, physicians, parents, and peers

2014 eMedicine Surgery

12. Gynecomastia

indications Palpable testicular mass Gynecomastia size >5 cm Persistent Gynecomastia without obvious cause Serum HCG increased Breast (and possibly FNA) indications suspected MRI brain suspected (increased ) IX. Management Evaluate for underlying cause Physiologic cause is a diagnosis of exclusion Observation Indicated in most cases Routine follow-up on an every 6 month basis Medical management Indicated in symptomatic or distressing Gynecomastia 10 mg daily for 3 months ( ) 60 mg daily for 3-9 months (...) Enlargement , Benign Gynecomastia of Adolescence , Familial Gynecomastia II. Causes: Physiologic in Newborn, Puberty, Older men Physiologic Mechanisms excess Decreased androgen to ratio Physiologic syndromes (25% of cases) Gynecomastia in the newborn Common response to maternal s enlargement usually resolves in weeks May be accompanied by milk discharge (witch's milk) Benign Gynecomastia of Adolescence Frequently occurs in boys at mid to late Asymmetric involvement and tenderness Resolves spontaneously

2015 FP Notebook

13. Medicalization of aging and the testosterone deficiency syndrome

Medicalization of aging and the testosterone deficiency syndrome Servicio Navarro de Salud / Osasunbidea Plaza de la Paz, s/n - 31002 Pamplona T 848429047 - F 848429010 farmacia.atprimaria@cfnavarra.es Drug and Therapeutics Bulletin of Navarre. Spain abstract n Objective: to carry out a critical appraisal of the Testosterone Deficit Syndrome (TDS), also known as low testosterone or T-low, its diagnosis and management. Materials and methods: a bibliographic search was carried out in the TRIP (...) there is no clear benefit in the relevant primary endpoints and there are alarming results on the possible risks. Increasing consumption responds to the success of awareness raising campaigns. TDS is a clear example of disease mongering. Key words: Testosterone. Hypogonadism. Testosterone Deficiency Syndrome. Andropause. Disease mongering. Medicalization of aging and the testosterone deficiency syndrome JuaN GérvaS Family Physician. CESCa group, Madrid, Spain ENriquE GaviláN Family Physician, Montehermoso

2012 Drug and Therapeutics Bulletin of Navarre (Spain)

14. Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients

Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients POGO Antineoplastic – Induced Nausea and Vomiting Guideline Development Panel: L. Lee Dupuis MScPhm, ACPR, FCSHP Sabrina Boodhan BScPhm, ACPR Lillian Sung MD, PhD Carol Portwine MD, FRCPC, PhD Richard Hain MD Patricia McCarthy RN, (EC), MSc(A) Mark (...) and the expert consensus of the POGO Antineoplastic–induced Nausea and Vomiting Guideline Development Group, the following classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients is recommended: Recommendation: The single antineoplastic agents provided in Table 1 have high, moderate, low or minimal emetogenic potential in children. Table 1: Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients Given

2010 SickKids Supportive Care Guidelines

15. Gynecomastia

intolerance, and diarrhea (hyperthyroidism) Past medical history should address disorders that can cause gynecomastia and include a history of all prescribed and OTC drugs. Physical examination Complete examination is done, including assessment of vital signs, skin, and general appearance. The neck is examined for goiter. The abdomen is examined for ascites, venous distention, and suspected adrenal masses. Development of secondary sexual characteristics (eg, the penis, pubic hair, and axillary hair (...) Gynecomastia Gynecomastia - Genitourinary Disorders - MSD Manual Professional Edition Brought to you by The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases / / / / IN THIS TOPIC OTHER TOPICS IN THIS CHAPTER Test your knowledge Acute Tubular Necrosis Which

2013 Merck Manual (19th Edition)

16. A Novel Mutation Causing 17-β-Hydroxysteroid Dehydrogenase Type 3 Deficiency in an Omani Child: First Case Report and Review of Literature (PubMed)

A Novel Mutation Causing 17-β-Hydroxysteroid Dehydrogenase Type 3 Deficiency in an Omani Child: First Case Report and Review of Literature This is the first case report in Oman and the Gulf region of a 17-β-hydroxysteroid dehydrogenase type 3 (17-β-HSD3) deficiency with a novel mutation in the HSD17B3 gene that has not been previously described in the medical literature. An Omani child was diagnosed with 17-β-HSD3 deficiency and was followed up for 11 years at the Pediatric Endocrinology (...) testosterone and low androstendiol glucurunide. Testosterone injections (50mg once monthly for six months) were given that resulted in significant reduction in his gynecomastia. Molecular analysis revealed a previously unreported homozygous variant in exon eight of the HSD17B3 gene (NM_000197.1:c.576G>A.Trp192*). This variant creates a premature stop codon, which is very likely to result in a truncated protein or loss of protein production. This is the first report in the medical literature of this novel

Full Text available with Trip Pro

2015 Oman medical journal

17. Which medications effectively reduce pubertal gynaecomastia?

Which medications effectively reduce pubertal gynaecomastia? BestBets: Which medications effectively reduce pubertal gynaecomastia? Which medications effectively reduce pubertal gynaecomastia? Report By: Dr Sarah L Maidment - Registrar in Paediatrics Institution: Paediatrics, Peterborough District Hospital, UK Date Submitted: 29th April 2010 Last Modified: 29th April 2010 Status: Green (complete) Three Part Question In [boys with pubertal gynaecomastia] is [anastrozole or tamoxifen] [effective (...) cantly during the treatment Comment(s) Pubertal gynaecomastia is breast enlargement without any pathological cause in adolescent boys. It is thought to arise from a transient imbalance between the stimulatory effects of oestrogens and the inhibitory effects of androgens on breast tissue during puberty. It is a common problem, affecting 48–64% of boys at puberty to some degree. In more than 90% of cases it resolves spontaneously within 3 years (Khan). However, gynaecomastia occurs at a time when boys

2010 BestBETS

18. MECHANISMS IN ENDOCRINOLOGY: Medical consequences of doping with anabolic androgenic steroids (AAS): effects on reproductive functions. (PubMed)

, infertility, and erectile dysfunction (anabolic steroid-induced hypogonadism). Should spermatogenesis not recover after AASs abuse, a pre-existing fertility disorder may have resurfaced. AASs frequently cause gynecomastia and acne. In women, AASs may disrupt ovarian function. Chronic strenuous physical activity leads to menstrual irregularities and, in severe cases, to the female athlete triad (low energy intake, menstrual disorders and low bone mass), making it difficult to disentangle the effects (...) of sports and AASs. Acne, hirsutism and (irreversible) deepening of the voice are further consequences of AASs misuse. There is no evidence that AASs cause breast carcinoma. Detecting AASs misuse through the control network of the World Anti-Doping Agency (WADA) not only aims to guarantee fair conditions for athletes, but also to protect them from medical sequelae of AASs abuse. © 2015 European Society of Endocrinology.

Full Text available with Trip Pro

2015 European Journal of Endocrinology

19. what drugs can cuse gynaecomastia? On stopping the medication how long will the symptoms of gynaecomastia( eg pain) take to go? Assuming it will settle.

of gynaecomastia( eg pain) take to go? Assuming it will settle. What drugs can cause gynaecomastia? On stopping the medication how long will the symptoms of gynaecomastia ( e.g. pain) take to go? GP notebook an online textbook contains a chapter on gynecomastia on drug induced gynecomastia it reports: “Drug-induced gynecomastia is common and may account for 20% to 25% of cases (1) .These may be categorised into: • oestrogens and oestrogen like drugs, for example diethylstiboestrol; exposure to partners using (...) and periodic follow-up are recommended in patients without an underlying pathology during appropriate work-up if a specific cause of gynecomastia can be identified, it should be addressed e.g. - offending medications should be withdrawn a reduction in tenderness softening of the glandular tissue will be evident within 1 month of discontinuation of the drug but in long standing cases (more than 1 year) due to the presence of fibrosis, substantial regression (spontaneously or with medical therapy

2013 TRIP Answers

20. Brilinta (ticagrelor) Tablets - medical review

Brilinta (ticagrelor) Tablets - medical review CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022433Orig1s000 MEDICAL REVIEW(S) DIVISION OF CARDIOVASCULAR AND RENAL PRODUCTS Complete Response Review Addendum Sponsor Safety Reporting Submissions: NDA 22-433 and IND 65,808 SD 632 Drug: ticagrelor (Brilinta™) Indication: reduce the rate of thrombotic events in patients with acute coronary syndromes (ACS) Sponsor: AstraZeneca Review date: June 8, 2011 Reviewer: Thomas A. Marciniak, M.D (...) . Medical Team Leader On April 20, 2011, we met with AstraZeneca (AZ) staff to discuss progress on the reviews of the complete response for NDA 22-433. Because my review and that of the IND reviewer, Dr. Martin Rose, had suggested significant problems with AZ’s handling of serious adverse events (SAEs), I added to the end of the agenda a discussion of these problems. The minutes for the meeting filed on May 19, 2011, summarize that discussion as follows: “There was some discussion regarding

2011 FDA - Drug Approval Package

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>